Serious riskFDA DrugClass I

Vitruvias Therapeutics thyroid tablets recalled for superpotent drug

Vitruvias Therapeutics is recalling Thyroid Tablets, USP 1/2 Grain (30 mg) because the tablets are superpotent—meaning they contain higher-than-intended levels of active ingredients. This lot was distributed nationwide. The affected lot number is 504950, expiring 09/30/2026.

From the FDA notice · Read the official notice ↗

What to do

  1. Check if you have lot #504950 of Vitruvias Therapeutics Thyroid Tablets, USP 1/2 Grain.
  2. Contact your pharmacy or doctor immediately if you have this lot.
  3. Do not stop taking your thyroid medication without speaking to your doctor first.
  4. Your doctor will advise whether to switch to a different lot or brand.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00.
Sold in
Nationwide
Made for
Adults (0 months and older)

Details

Units affected
1955 bottles
Illnesses reported
None reported
Manufactured in
778 N Dean Rd Ste 600, N/A, Auburn, AL, United States
Classification
Class I
Recall number
D-0866-2026

In the FDA's words

Description
Thyroid Tablets, USP, 1/2 Grain (30 mg), Each tablet contains: levothyroxine (T4) 19 mcg, liothyronine (T3) 4.5 mcg, 100 Tablets, Rx only, Distributed by: Vitruvias Therapeutics, Auburn, AL 36830, Product of USA, NDC 69680-166-00. Superpotent Drug Lot # 504950, Exp Date: 09/30/2026. Distribution: US Nationwide. Affected quantity: 1955 bottles
Hazard
Superpotent Drug

Related topics

PotencyDrugsSold nationwideMore from FDA Drug